Compositions attractive to mice include one or more additives. The additives can include 2-sec-butyl-4,5-dihydrothiazole and/or 3,4-dehydro-ero-brevicomin, which can be isolated, purified and/or synthetic. In addition to these additives, the compositions can also include a lethal agent, such as, an anticoagulant or a toxicant, a chemostenlant and/or food. Devices and methods of using the composition are also disclosed.

Compositions attractive to mice include one or more additives. The additives can include 2-sec-butyl-4,5-dihydrothiazole and/or 3,4-dehydro-ero-brevicomin, which can be isolated, purified and/or synthetic. In addition to these additives, the compositions can also include a lethal agent, such as, an anticoagulant or a toxicant, a chemostenlant and/or food. Devices and methods of using the composition are also disclosed.

Disclosed is a laevorotatory enantiomer of the configurational stereoisomer of difethialone, named homo-stereoisomer, the formula of which is 3-(4-bromobiphenyl-4-yl)-1-(4-hydroxythiocoumarin-3-yl)-1,2,3,4-tetrahydronaphthalene, in which carbons 1 and 3 of the 1,2,3,4-tetrahydronaphthalene group have the same absolute configuration.

Disclosed is a laevorotatory enantiomer of the configurational stereoisomer of difethialone, named homo-stereoisomer, the formula of which is 3-(4-bromobiphenyl-4-yl)-1-(4-hydroxythiocoumarin-3-yl)-1,2,3,4-tetrahydronaphthalene, in which carbons 1 and 3 of the 1,2,3,4-tetrahydronaphthalene group have the same absolute configuration.

Disclosed is a configurational stereoisomer, referred to as enantiomer E.sub.4, of flocoumafen, the enantiomer E.sub.4 having, as determined by the chromatographic analysis of flocoumafen including four configurational stereoisomers of flocoumafen, carried out under conditions described hereinafter, a retention time t.sub.4 with a value such that t.sub.1<t.sub.2<t.sub.3<t.sub.4; t.sub.1, t.sub.2 and t.sub.3 representing the retention times of the configurational stereoisomers of flocoumafen different from the enantiomer E.sub.4, the analysis being carried out at a temperature of 23.5 C.

Disclosed is a configurational stereoisomer, referred to as enantiomer E.sub.4, of flocoumafen, the enantiomer E.sub.4 having, as determined by the chromatographic analysis of flocoumafen including four configurational stereoisomers of flocoumafen, carried out under conditions described hereinafter, a retention time t.sub.4 with a value such that t.sub.1<t.sub.2<t.sub.3<t.sub.4; t.sub.1, t.sub.2 and t.sub.3 representing the retention times of the configurational stereoisomers of flocoumafen different from the enantiomer E.sub.4, the analysis being carried out at a temperature of 23.5 C.

Disclosed is a configurational stereoisomer, named enantiomer E.sub.1, of flocoumafen, the enantiomer E.sub.1 having, by chromatographic analysis of flocoumafen performed under particular conditions, a retention time t.sub.1 having a value such that t.sub.1<t.sub.2<t.sub.3<t.sub.4; t.sub.2, t.sub.3 and t.sub.4 representing the retention times of the configurational stereoisomers of flocoumafen different from the enantiomer E.sub.1, the analysis being performed at a temperature of 23.5 C.

Disclosed is a configurational stereoisomer, named enantiomer E.sub.1, of flocoumafen, the enantiomer E.sub.1 having, by chromatographic analysis of flocoumafen performed under particular conditions, a retention time t.sub.1 having a value such that t.sub.1<t.sub.2<t.sub.3<t.sub.4; t.sub.2, t.sub.3 and t.sub.4 representing the retention times of the configurational stereoisomers of flocoumafen different from the enantiomer E.sub.1, the analysis being performed at a temperature of 23.5 C.

Disclosed is a composition including flocoumafen and an amount of a configurational stereoisomer of flocoumafen, named enantiomer E.sub.4, such that the ratio of this amount to the amount of flocoumafen in the composition is less than 10%, the enantiomer E.sub.4 being present with the exclusion of a racemic mixture, the enantiomer E.sub.4 having, by chromatographic analysis of flocoumafen, a retention time t.sub.4 having a value such that t.sub.1<t.sub.2<t.sub.3<t.sub.4; t.sub.1, t.sub.2 and t.sub.3 representing the retention times of the configurational stereoisomers of flocoumafen different from the enantiomer E.sub.4, the chromatographic analysis being performed at a temperature of 23.5 C.

Disclosed is a composition including flocoumafen and an amount of a configurational stereoisomer of flocoumafen, named enantiomer E.sub.4, such that the ratio of this amount to the amount of flocoumafen in the composition is less than 10%, the enantiomer E.sub.4 being present with the exclusion of a racemic mixture, the enantiomer E.sub.4 having, by chromatographic analysis of flocoumafen, a retention time t.sub.4 having a value such that t.sub.1<t.sub.2<t.sub.3<t.sub.4; t.sub.1, t.sub.2 and t.sub.3 representing the retention times of the configurational stereoisomers of flocoumafen different from the enantiomer E.sub.4, the chromatographic analysis being performed at a temperature of 23.5 C.